Nasdaq

SKYRIZI® (risankizumab-rzaa) Now Available in the U.S. as a Single 150 mg Injection for Adults with Moderate to Severe Plaque Psoriasis

- SKYRIZI is now the only four-dose-a-year biologic for psoriasis with options to administer via a single-dose pen or prefilled syringe NORTH CHICAGO, Ill., Aug. 9, 2021 /PRNewswire/ -- AbbVie (NYSE: ...
Healio

Risankizumab improves moderate to severe plaque psoriasis for up to 5 years

Please provide your email address to receive an email when new articles are posted on . 85.1% of patients achieved PASI 90 and 52.3% achieved PASI 100 at week 256. The rates of treatment-emergent ...
The New England Journal of Medicine

Risankizumab in Severe Asthma — A Phase 2a, Placebo-Controlled Trial

Interleukin-23 has been implicated in airway inflammation that is mediated by type 2 and type 17 cytokines. Whether targeting interleukin-23 in the treatment of asthma improves disease control and ...
The Globe and Mail

AbbVie Advances Risankizumab Delivery With On‑Body Injector Study Completion

AbbVie has completed a Phase 1 study titled “A Phase 1 Pharmacokinetic Study in Healthy Subjects to Evaluate the Bioavailability of Risankizumab Subcutaneous Administration With On-Body Injector ...
Healio

Risankizumab outperforms apremilast as plaque psoriasis treatment in phase 4 study

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. At week 16, 55.9% of the risankizumab group and 5.1% of ...
The American Journal of Managed Care

Patients in Risankizumab Phase 2a Trial Saw Some Asthma Symptoms Increase

Risankizumab, a biologic, is used for psoriasis, but whether it can improve asthma control has been unclear. A study released Thursday in The New England Journal of Medicine of risankizumab for the ...
Medscape

Placebo Beat Risankizumab in Adults With Severe Asthma

Placebo treatment was found to be superior to treatment with risankizumab with respect to time to first asthma worsening and annualized rate of asthma worsening for adults with severe persistent ...
Medical Xpress

High-dose risankizumab trial tests staying power against psoriasis

Oregon Medical Research Center in Portland, Oregon, has led a phase 2 trial in moderate-to-severe plaque psoriasis that paired higher-than-approved doses of risankizumab with extended follow-up and ...
Monthly Prescribing Reference

Risankizumab Bests Apremilast in Head-to-Head Plaque Psoriasis Study

Credit: Thinkstock. Risankizumab is an interlekin-23 inhibitor; apremilast is a phosphodiesterase 4 inhibitor. Risankizumab (Skyrizi ®) was found to significantly improve clinical outcomes in patients ...
Medscape

Risankizumab Has Early and Lasting Benefits in Crohn's Disease

LAS VEGAS, Nevada — Risankizumab (Skyrizi) provides early and lasting benefits for patients with Crohn's disease, phase 3 trials indicate. Based on these and other recent findings, the drug could be ...
Monthly Prescribing Reference

Risankizumab vs Ustekinumab in Patients With Crohn Disease: Trial Results

Topline results were announced from a head-to-head study comparing risankizumab (Skyrizi ®) to ustekinumab (Stelara ®) in patients with moderately to severely active Crohn disease who have failed at ...